{
    "organizations": [],
    "uuid": "60408545b3e0c0c96b6bf2578efe4e0fdd406a56",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-acelrx-pharma-q4-loss-per-share-02/brief-acelrx-pharma-q4-loss-per-share-0-20-idUSASB0C9K9",
    "ord_in_thread": 0,
    "title": "BRIEF-AcelRx Pharma Q4 Loss Per Share $0.20",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 8 (Reuters) - AcelRx Pharmaceuticals Inc:\n* ACELRX PHARMACEUTICALS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS\n* Q4 LOSS PER SHARE $0.20 * Q4 EARNINGS PER SHARE VIEW $-0.20 â€” THOMSON REUTERS I/B/E/S\n* ANTICIPATED PDUFA DATE FOR DSUVIA IN Q4 2018 * EXPECTED FDA ADVISORY COMMITTEE MEETING FOR DSUVIA IN Q3 2018\n* ANTICIPATES RESUBMISSION OF NDA FOR ZALVISO IN H2 2018 * QTRLY TOTAL REVENUE 740,000 Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-03-09T05:29:00.000+02:00",
    "crawled": "2018-03-09T14:13:22.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "acelrx",
        "pharmaceutical",
        "inc",
        "acelrx",
        "pharmaceutical",
        "report",
        "fourth",
        "quarter",
        "financial",
        "result",
        "q4",
        "loss",
        "per",
        "share",
        "q4",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "anticipated",
        "pdufa",
        "date",
        "dsuvia",
        "q4",
        "expected",
        "fda",
        "advisory",
        "committee",
        "meeting",
        "dsuvia",
        "q3",
        "anticipates",
        "resubmission",
        "nda",
        "zalviso",
        "h2",
        "qtrly",
        "total",
        "revenue",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}